IDH2 and astrocytoma (excluding glioblastoma): In particular, IDH mutations are now considered as a disease-defining feature of oligodendrogliomas and astrocytomas, while IDH wildtype gliomas (designated as glioblastomas) are recognized as a separate, more aggressive disease with distinct molecular genetics [15,16,17].